Share page on LinkedIn

ICON is a global provider of outsourced development services

ICON currently has almost 15,250 employees in 94 locations in 40 countries. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

ICON services video

Financial figures

  • Full year reported revenue for 2019 was $2.8 billion, representing an 8.1% year on year increase or 9.6% on a constant currency basis. At the end of Q3 2020 the company had a record closing backlog of $9.4 billion, an increase of 11.8% year on year (see Q3 earnings release).
  • Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and 13.1% increase on Quarter 2 2020.

  • Adjusted earnings per share attributable to the Group for the quarter of $1.72, compared to $1.74 in Quarter 3 2019. Year to date earnings per share* attributable to the group of $4.63, compared to $5.06 for the equivalent prior year period.

  • Strong balance sheet and liquidity position remains, exceptional cash generation delivers net cash position of $360 million. Days sales outstanding reduced to 45 days from 56 days at September 30, 2019.

  • Successful refinance of the existing private placement $350 million senior notes on a delayed drawdown basis.

  • Raising full year 2020 revenue guidance to a range of $2,750 - $2,810 million. Full Year 2020 earnings per share guidance in the range of $6.35 - $6.50.

Q3 2020 financial results

How ICON partners with sponsors and pharma